Lilly is betting big on retatrutide as the next pillar of its obesity portfolio after its weight loss injection Zepbound and ...

Earlier deployment of ARPIs, PARP inhibitors, and PSMA radioligand therapy yields deeper initial control but creates heavily pretreated mCRPC with complex resistance and cumulative toxicity ...

GIP obesity drug enters Phase 3 with strong cash runway, but rising competition and trial risk. Click for this VKTX update.

Adding a fourth oral antidiabetic drug to a triple regimen beats metformin dose escalation for achieving glycemic control.

L1, EBV and mismatch repair deficiency suggests CLDN18.2 stratification must be integrated into multi-biomarker algorithms rather than used in isolation. Treatment interactions emerged: CLDN18.2-high ...

Chief Executive Officer — Dr. Sergio Traversa Chief Medical Officer, Oncology — Dr. Raj S. Pruthi Chief Financial Officer — Maged S. Shenouda With me on today's call are Relmada Therapeutics, Inc.'s ...

Finerenone demonstrated safety and reduced albuminuria for patients with chronic kidney disease, type 2 diabetes and a ...

A randomized phase 2 maintenance strategy with cabozantinib 60 mg daily for up to 2 years failed to improve 4-month PFS versus placebo in high-grade uterine sarcomas. Median PFS was identical at 3.7 ...

With March marking National Colorectal Cancer Awareness Month, here’s what to know about colorectal cancer — including ...

Not a subscriber? Sign up here to get this newsletter in your inbox. In today’s issue: Hello, and welcome to Health Brief. While Republicans in the House are sussing out which policies they want to ...

Social Vulnerability Index scores inversely correlated with dietary fiber intake, suggesting social determinants may shape diet patterns relevant to microbiome-associated immunotherapy response. Whole ...

The Fork Cancer Gala in Pensacola offers a night of fine dining and live music to support cancer patients' transportation needs.